KR20130055619A - 접합된 혈액 응고 인자 viii - Google Patents

접합된 혈액 응고 인자 viii Download PDF

Info

Publication number
KR20130055619A
KR20130055619A KR1020127031386A KR20127031386A KR20130055619A KR 20130055619 A KR20130055619 A KR 20130055619A KR 1020127031386 A KR1020127031386 A KR 1020127031386A KR 20127031386 A KR20127031386 A KR 20127031386A KR 20130055619 A KR20130055619 A KR 20130055619A
Authority
KR
South Korea
Prior art keywords
fviii
group
biocompatible polymer
pharmaceutical composition
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127031386A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 헨리
Original Assignee
캔탭 바이오팔마수티칼 패턴트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20130055619(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 캔탭 바이오팔마수티칼 패턴트 리미티드 filed Critical 캔탭 바이오팔마수티칼 패턴트 리미티드
Publication of KR20130055619A publication Critical patent/KR20130055619A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020127031386A 2010-04-30 2011-04-28 접합된 혈액 응고 인자 viii Ceased KR20130055619A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII
GB1007357.5 2010-04-30
PCT/GB2011/000662 WO2011135307A1 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viii

Publications (1)

Publication Number Publication Date
KR20130055619A true KR20130055619A (ko) 2013-05-28

Family

ID=42289987

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127031386A Ceased KR20130055619A (ko) 2010-04-30 2011-04-28 접합된 혈액 응고 인자 viii

Country Status (26)

Country Link
US (1) US20130150302A1 (https=)
EP (1) EP2563402A1 (https=)
JP (1) JP5870088B2 (https=)
KR (1) KR20130055619A (https=)
CN (1) CN102939108A (https=)
AP (1) AP2012006575A0 (https=)
AU (1) AU2011247147B2 (https=)
BR (1) BR112012027590A2 (https=)
CA (1) CA2797058A1 (https=)
CL (1) CL2012003039A1 (https=)
CO (1) CO6660443A2 (https=)
CR (1) CR20120579A (https=)
EA (1) EA201290938A1 (https=)
EC (1) ECSP12012314A (https=)
GB (2) GB201007357D0 (https=)
IL (1) IL222566A (https=)
MX (1) MX2012012683A (https=)
MY (1) MY160922A (https=)
NI (1) NI201200160A (https=)
NZ (1) NZ603939A (https=)
PE (1) PE20130254A1 (https=)
PH (1) PH12012502150A1 (https=)
RU (1) RU2012144555A (https=)
SG (1) SG184906A1 (https=)
WO (1) WO2011135307A1 (https=)
ZA (1) ZA201208989B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
MX2020012103A (es) 2018-05-18 2021-01-29 Zhengzhou Gensciences Inc Proteina de fusion fviii mejorada y uso de la misma.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
PT2363414T (pt) * 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
CN101163506B (zh) * 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
CN101820920B (zh) 2007-10-09 2014-08-06 宝力泰锐克斯有限公司 新的缀合蛋白质和肽
DK2280734T3 (da) * 2008-04-24 2014-05-26 Cantab Biopharmaceuticals Patents Ltd Faktor-ix-konjugater med forlængede halveringstider
AU2009275358C1 (en) * 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Also Published As

Publication number Publication date
CL2012003039A1 (es) 2014-01-24
MY160922A (en) 2017-03-31
JP5870088B2 (ja) 2016-02-24
HK1173946A1 (en) 2013-05-31
IL222566A0 (en) 2012-12-31
RU2012144555A (ru) 2014-06-10
IL222566A (en) 2017-12-31
ZA201208989B (en) 2014-02-26
GB2492935A8 (en) 2014-10-29
US20130150302A1 (en) 2013-06-13
GB201220667D0 (en) 2013-01-02
AP2012006575A0 (en) 2012-12-31
ECSP12012314A (es) 2013-05-31
SG184906A1 (en) 2012-11-29
PE20130254A1 (es) 2013-03-16
GB201007357D0 (en) 2010-06-16
GB2492935B (en) 2014-04-30
CR20120579A (es) 2013-04-25
BR112012027590A2 (pt) 2016-08-09
PH12012502150A1 (en) 2013-02-04
NZ603939A (en) 2013-08-30
AU2011247147A1 (en) 2013-01-10
EA201290938A1 (ru) 2013-04-30
CN102939108A (zh) 2013-02-20
GB2492935A (en) 2013-01-16
JP2013525414A (ja) 2013-06-20
GB2492935B8 (en) 2014-10-29
CO6660443A2 (es) 2013-04-30
WO2011135307A1 (en) 2011-11-03
EP2563402A1 (en) 2013-03-06
MX2012012683A (es) 2013-04-03
NI201200160A (es) 2013-04-19
AU2011247147B2 (en) 2014-09-18
CA2797058A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
AU2011247147B2 (en) Conjugated blood coagulation Factor VIII
EP2563403B1 (en) Conjugate of blood coagulation factor viia and peg
CN102112156B (zh) 凝血因子viii聚合物偶联物
AU2009239641B2 (en) Factor IX conjugates with extended half-lives
TWI708611B (zh) 聚乙二醇化介白素-１１之組合物及方法
JP2015155469A (ja) 第ｆｖｉｉｉ因子ポリマー結合体
AU2019222949B2 (en) Factor VIII polymer conjugates
HK1155939B (en) Factor viii polymer conjugates
JP2018115170A (ja) 第ｆｖｉｉｉ因子ポリマー結合体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160225

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161001

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161219

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161001

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I